The Danish drugmaker has expanded its diabetes treatment range in Thailand, while preparing specialist training as competition intensifies in the GLP-1 medicines market.
Novo Nordisk has introduced a higher-dose semaglutide option in Thailand, widening the range of treatments available to adults with type 2 diabetes as the Danish drugmaker seeks to expand its presence in one of Asia’s more active diabetes markets. According to the company’s announcement on 7 October, the launch is intended to give doctors and patients another choice in managing a condition that remains a major health burden in the country.
At the launch event, more than 500 healthcare professionals gathered to discuss diabetes care and the new treatment option, the company said. Novo Nordisk Thailand general manager Cihan Serdar Kizilcik used the occasion to frame diabetes as a challenge that goes beyond glucose control, saying patients should also speak with their doctors about heart and kidney health. The company said the new medicine broadens therapeutic options for Thai clinicians, although it did not specify the brand name or the exact dose in its announcement.
The move comes as manufacturers of GLP-1 medicines, the class that includes semaglutide, compete for patients with type 2 diabetes and, increasingly, those seeking medicines that can also support weight management. Industry reporting suggests Novo Nordisk is keen to defend market share as rival treatments and lower-cost alternatives become more visible. That commercial backdrop helps explain why the company is also planning clinical symposiums across provincial medical hubs next year to train specialists on prescribing the higher-dose formulation.
Novo Nordisk said it has worked with Thailand’s diabetes community for more than 40 years, underscoring the company’s long-standing interest in the market. That history also reflects the broader shift in diabetes care towards therapies that aim to address not only blood sugar, but also cardiovascular and kidney risks, which are increasingly central to treatment discussions.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
